Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease

BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio

Read more at globenewswire.com